TB-500 finds primary use in soft tissue injuries, chronic tendinopathies, joint inflammation, and post-surgical recovery
Two practical points follow
ncbi.nlm.nih.gov/pmc/articles/PMC3206257 Sikiric P, et al
What This Means Clinically For patients who have tried GLP-1 medications and experienced significant side effects, or who are not candidates for appetite-suppressing approaches, AOD 9604 represents a mechanistically different option
Women of childbearing potential should employ reliable contraception during BPC-157 treatment if used clinically, pending establishment of safety in pregnancy
No concern about IGF-1-related side effects (joint pain, acromegaly risk at extreme doses)